Software adaptation framework for COPD disease
Chronic obstructive pulmonary disease (COPD) is one of the most severe public health problems worldwide. Pervasive and context aware computing create a new opportunity to redesign the traditional…
Chronic obstructive pulmonary disease (COPD) is a form of lung illness that progresses and is characterised by persistent respiratory symptoms and restricted airflow. A cough that may or may not produce mucus and shortness of breath are the prominent symptoms. Daily tasks like walking and getting dressed become more challenging as COPD becomes worse. Despite being incurable, COPD is treatable and preventive. Emphysema and chronic bronchitis are the two most prevalent forms of COPD and have historically been considered its two primary phenotypes. In order to cause lasting damage to the lung tissue, emphysema is characterised by expanded airspaces (alveoli) whose walls have collapsed. A productive cough that lasts at least three months for at least two years is considered to be a sign of chronic bronchitis. When both symptoms are not classified as COPD, they can both occur without limiting airflow. Emphysema is simply one of the anatomical disorders that can restrict airflow and can present in a large proportion of people without restricting airflow. Although chronic bronchitis does not usually cause airway restriction, young individuals who smoke have a greater chance of developing COPD. Emphysema and chronic bronchitis were frequently mentioned in previous definitions of COPD, however they were never mentioned in the GOLD report criteria.
Speaker lineup for this track will be announced soon.
Browse all speakers →Chronic obstructive pulmonary disease (COPD) is one of the most severe public health problems worldwide. Pervasive and context aware computing create a new opportunity to redesign the traditional…
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Oral and poster slots for original Chronic Lung Disease work, reviewed by the scientific committee.
Meet public health researchers, educators, and policy leaders from around the world across three days.
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Plenary lectures from leading voices shaping Chronic Lung Disease research and practice.
Attend in person in Singapore or join virtually — same programme, same certificate.
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
The Chronic Lung Disease track is a dedicated stream within IPHC 2027 covering the latest research, innovation, and best practice in Chronic Lung Disease. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Public health researchers, practitioners, epidemiologists, educators, doctoral students, and policy leaders with an interest in Chronic Lung Disease are all welcome — whether presenting or attending.
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Yes. IPHC 2027 is a hybrid conference — attend the Chronic Lung Disease track in person in Singapore or join live online, with on-demand access afterward.
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.